$CORT
Corcept Therapeutics Inc Stock $cort

$cort Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000162828024019610 Filed on May 01, 2024

Income Statement

Concept	2024 Q2	2024 Q1	2023 Q4
Revenue	$163.8M	$146.8M	$135.4M
YoY Change	39.15%	38.95%	31.39%
Cost Of Revenue	$2.524M	$2.535M	$1.877M
YoY Change	60.36%	82.9%	26.82%
Gross Profit	$161.3M	$144.3M	$133.5M
YoY Change	38.86%	38.37%	31.46%
Gross Profit Margin	98.46%	98.27%	98.61%
Selling, General & Admin	$66.94M	$56.27M	$47.15M
YoY Change	54.65%	15.86%	11.41%
% of Gross Profit	41.5%	39.0%	35.31%
Research & Development	$58.75M	$58.51M	$54.71M
YoY Change	35.74%	43.22%	48.85%
% of Gross Profit	36.43%	40.55%	40.97%
Depreciation & Amortization	$128.0K	$68.00K	$542.0K
YoY Change	-31.18%	-60.47%	196.17%
% of Gross Profit	0.08%	0.05%	0.41%
Operating Expenses	$125.7M	$114.8M	$101.9M
YoY Change	45.2%	28.36%	28.81%
Operating Profit	$35.59M	$29.50M	$31.67M
YoY Change	20.31%	98.61%	40.76%
Interest Expense	$6.004M	$5.493M	$5.140M
YoY Change	79.38%	53.39%	189.25%
% of Operating Profit	16.87%	18.62%	16.23%
Other Income/Expense, Net	$6.004M	$5.493M
YoY Change	79.38%	53.39%
Pretax Income	$41.60M	$34.99M	$36.81M
YoY Change	26.32%	89.83%	51.63%
Income Tax	$6.100M	$7.200M	$5.454M
% Of Pretax Income	14.66%	20.58%	14.82%
Net Earnings	$35.49M	$27.76M	$31.36M
YoY Change	28.92%	74.83%	88.87%
Net Earnings / Revenue	21.67%	18.91%	23.16%
Basic Earnings Per Share	$0.34	$0.27
Diluted Earnings Per Share	$0.32	$0.25	$0.28
COMMON SHARES
Basic Shares Outstanding	104.1M shares	103.5M shares	103.1M shares
Diluted Shares Outstanding	111.2M shares	109.9M shares

Balance Sheet

Concept	2024 Q2	2024 Q1	2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$473.2M	$410.8M	$368.2M
YoY Change	30.25%	-11.68%	-14.7%
Cash & Equivalents	$128.6M	$149.8M	$135.6M
Short-Term Investments	$344.6M	$261.0M	$232.7M
Other Short-Term Assets	$9.126M	$18.36M	$41.56M
YoY Change	-69.44%	-38.55%	36.61%
Inventory	$8.350M	$7.190M	$7.730M
Prepaid Expenses	$5.146M	$5.542M	$4.319M
Receivables	$53.84M	$61.52M	$41.12M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$560.8M	$503.4M	$458.6M
YoY Change	29.65%	-5.72%	-8.14%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.472M	$127.0K	$195.0K
YoY Change	127.16%	-72.45%	-69.19%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$19.32M	$40.28M	$57.18M
YoY Change			1055.77%
Other Assets	$6.939M	$6.388M	$6.541M
YoY Change	-92.41%	34.09%	29.32%
Total Long-Term Assets	$153.7M	$152.6M	$162.9M
YoY Change	67.01%	81.73%	93.5%
TOTAL ASSETS
Total Short-Term Assets	$560.8M	$503.4M	$458.6M
Total Long-Term Assets	$153.7M	$152.6M	$162.9M
Total Assets	$714.6M	$655.9M	$621.5M
YoY Change	36.2%	6.16%	6.53%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$19.48M	$12.56M	$17.40M
YoY Change	144.28%	11.96%	45.26%
Accrued Expenses	$59.25M	$59.74M	$51.63M
YoY Change	-9.67%	52.83%	67.63%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$100.8M	$97.20M	$104.5M
YoY Change	8.26%	23.25%	44.16%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$17.56M	$10.87M	$10.31M
YoY Change	76.47%	15.64%	13.3%
Total Long-Term Liabilities	$17.56M	$10.87M	$10.31M
YoY Change	76.47%	15.64%	13.3%
TOTAL LIABILITIES
Total Short-Term Liabilities	$100.8M	$97.20M	$104.5M
Total Long-Term Liabilities	$17.56M	$10.87M	$10.31M
Total Liabilities	$118.3M	$108.1M	$114.8M
YoY Change	14.85%	22.44%	40.72%
SHAREHOLDERS EQUITY
Retained Earnings	$465.8M	$430.3M	$402.5M
YoY Change	37.08%	37.8%	35.81%
Common Stock	$781.1M	$758.2M	$738.5M
YoY Change	12.26%	11.51%	563651.91%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$596.2M	$547.9M	$506.7M
YoY Change
Total Liabilities & Shareholders Equity	$714.6M	$655.9M	$621.5M
YoY Change	36.2%	6.16%	6.53%

Cashflow Statement

Concept	2024 Q2	2024 Q1	2023 Q4
OPERATING ACTIVITIES
Net Income	$35.49M	$27.76M	$31.36M
YoY Change	28.92%	74.83%	88.87%
Depreciation, Depletion And Amortization	$128.0K	$68.00K	$542.0K
YoY Change	-31.18%	-60.47%	196.17%
Cash From Operating Activities	$41.18M	$23.76M	$5.839M
YoY Change	-2.61%	-8.48%	-82.51%
INVESTING ACTIVITIES
Capital Expenditures	$416.0K		$39.00K
YoY Change	307.84%		25.81%
Acquisitions
YoY Change
Other Investing Activities	-$59.78M	-$9.014M	$17.14M
YoY Change	149.13%	-104.34%	-199.62%
Cash From Investing Activities	-$60.19M	-$9.014M	$17.11M
YoY Change	149.8%	-104.34%	-199.22%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-2.150M	-$543.0K	777.0K
YoY Change	-98.52%	-400.0%	-1373.77%
NET CHANGE
Cash From Operating Activities	41.18M	$23.76M	5.839M
Cash From Investing Activities	-60.19M	-$9.014M	17.11M
Cash From Financing Activities	-2.150M	-$543.0K	777.0K
Net Change In Cash	-21.16M	$14.20M	23.72M
YoY Change	-83.41%	-93.92%	47.47%
FREE CASH FLOW
Cash From Operating Activities	$41.18M	$23.76M	$5.839M
Capital Expenditures	$416.0K		$39.00K
Free Cash Flow	$40.77M		$5.800M
YoY Change	-3.36%		-82.61%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q1	us-gaap	Accrued Income Taxes Noncurrent AccruedIncomeTaxesNoncurrent	10869000	usd
CY2023Q4	us-gaap	Accrued Income Taxes Noncurrent AccruedIncomeTaxesNoncurrent	10307000	usd
CY2024Q1	us-gaap	Liabilities Liabilities	108071000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	114812000	usd
CY2024Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q1	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	641059000	usd
CY2023Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	635078000	usd
CY2024Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	758244000	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	738515000	usd
CY2024Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	258000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	609000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	430288000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	402526000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	506705000	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	655935000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	621517000	usd
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	146808000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	105654000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	547864000	usd
CY2024Q1	cort	Accrued Clinical Expenses Current AccruedClinicalExpensesCurrent	24825000	usd
CY2023Q4	cort	Accrued Clinical Expenses Current AccruedClinicalExpensesCurrent	21330000	usd
CY2024Q1	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	usd
CY2023Q4	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	usd
CY2024Q1	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	133000	usd
CY2023Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	133000	usd
CY2024Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2535000	usd
CY2023Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1386000	usd
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	58505000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	40851000	usd
CY2024Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	56268000	usd
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	48564000	usd
CY2024Q1	us-gaap	Costs And Expenses CostsAndExpenses	117308000	usd
CY2023Q1	us-gaap	Costs And Expenses CostsAndExpenses	90801000	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	29500000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	14853000	usd
CY2024Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	5493000	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	3581000	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	34993000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	18434000	usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	7231000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2555000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	27762000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	15879000	usd
CY2024Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	27514000	usd
CY2024Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	27514000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	15807000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	15807000	usd
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.27
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.15
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.25
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.14
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	102791000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	107885000	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	109915000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	115425000	shares
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	27762000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	15879000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	103000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	-192000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-330000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	605000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-21000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	111000	usd
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	27411000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	16595000	usd
CY2024Q1	us-gaap	Profit Loss ProfitLoss	27762000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	15879000	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	13249000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	11141000	usd
CY2024Q1	cort	Accretion Expense Income AccretionExpenseIncome	-2859000	usd
CY2023Q1	cort	Accretion Expense Income AccretionExpenseIncome	-1503000	usd
CY2024Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	52000	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	119000	usd
CY2024Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	68000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	172000	usd
CY2024Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-7162000	usd
CY2023Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-6726000	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	59000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	568000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	20395000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1500000	usd
CY2024Q1	us-gaap	Increase Decrease In Insurance Settlements Receivable IncreaseDecreaseInInsuranceSettlementsReceivable	-14000000	usd
CY2023Q1	us-gaap	Increase Decrease In Insurance Settlements Receivable IncreaseDecreaseInInsuranceSettlementsReceivable	0	usd
CY2024Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-983000	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-558000	usd
CY2024Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-3612000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-729000	usd
CY2024Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-153000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	0	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-4861000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-649000	usd
CY2024Q1	cort	Increase Decrease In Accrued Clinical Expenses IncreaseDecreaseInAccruedClinicalExpenses	3494000	usd
CY2023Q1	cort	Increase Decrease In Accrued Clinical Expenses IncreaseDecreaseInAccruedClinicalExpenses	-592000	usd
CY2024Q1	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	9114000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	8027000	usd
CY2024Q1	cort	Increase Decrease In Accrued Settlement Litigation Liabilities IncreaseDecreaseInAccruedSettlementLitigationLiabilities	-14000000	usd
CY2023Q1	cort	Increase Decrease In Accrued Settlement Litigation Liabilities IncreaseDecreaseInAccruedSettlementLitigationLiabilities	0	usd
CY2024Q1	us-gaap	Increase Decrease In Accrued Taxes Payable IncreaseDecreaseInAccruedTaxesPayable	562000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Taxes Payable IncreaseDecreaseInAccruedTaxesPayable	302000	usd
CY2024Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-75000	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-568000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	23756000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	25957000	usd
CY2024Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	68862000	usd
CY2023Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	207475000	usd
CY2024Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	77876000	usd
CY2023Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	0	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-9014000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	207475000	usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	749000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	1409000	usd
CY2024Q1	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	940000	usd
CY2023Q1	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	0	usd
CY2024Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	476000	usd
CY2023Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	usd
CY2024Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1756000	usd
CY2023Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1228000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-543000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	181000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	14199000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	233613000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	135551000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	66329000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	149750000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	299942000	usd
CY2024Q1	cort	Shares Repurchased In Net Settlement Of Cashless Option Exercise SharesRepurchasedInNetSettlementOfCashlessOptionExercise	1798000	usd
CY2023Q1	cort	Shares Repurchased In Net Settlement Of Cashless Option Exercise SharesRepurchasedInNetSettlementOfCashlessOptionExercise	5246000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	506705000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3485000	usd
CY2024Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	3554000	usd
CY2024Q1	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	476000	usd
CY2024Q1	cort	Treasury Stock Value Acquired Excise Tax TreasuryStockValueAcquiredExciseTax	81000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	12929000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	1283000	usd
CY2024Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-351000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	27762000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	547864000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	501842000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	6540000	usd
CY2023Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	6359000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10966000	usd
CY2023Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	716000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	15879000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	529584000	usd
CY2024Q1	cort	Number Of Series Of Selective Cortisol Modulators NumberOfSeriesOfSelectiveCortisolModulators	4	series
CY2024Q1	cort	Inventory Raw Materials Current And Noncurrent InventoryRawMaterialsCurrentAndNoncurrent	704000	usd
CY2023Q4	cort	Inventory Raw Materials Current And Noncurrent InventoryRawMaterialsCurrentAndNoncurrent	0	usd
CY2024Q1	cort	Inventory Work In Process Current And Noncurrent InventoryWorkInProcessCurrentAndNoncurrent	7132000	usd
CY2023Q4	cort	Inventory Work In Process Current And Noncurrent InventoryWorkInProcessCurrentAndNoncurrent	8233000	usd
CY2024Q1	cort	Inventory Finished Goods Current And Noncurrent InventoryFinishedGoodsCurrentAndNoncurrent	7200000	usd
CY2023Q4	cort	Inventory Finished Goods Current And Noncurrent InventoryFinishedGoodsCurrentAndNoncurrent	7741000	usd
CY2024Q1	cort	Inventory Current Noncurrent InventoryCurrentNoncurrent	15036000	usd
CY2023Q4	cort	Inventory Current Noncurrent InventoryCurrentNoncurrent	15974000	usd
CY2024Q1	us-gaap	Inventory Noncurrent InventoryNoncurrent	7846000	usd
CY2023Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	8244000	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	7190000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	7730000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	387016000	usd
CY2024Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	5542000	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	4319000	usd
CY2024Q1	us-gaap	Other Assets Current OtherAssetsCurrent	18356000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	23243000	usd
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	23898000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	27562000	usd
CY2024Q1	cort	Accrued Government Rebate Current AccruedGovernmentRebateCurrent	27539000	usd
CY2023Q4	cort	Accrued Government Rebate Current AccruedGovernmentRebateCurrent	18468000	usd
CY2024Q1	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	13458000	usd
CY2023Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	1814000	usd
CY2024Q1	cort	Accrued Compensation Current AccruedCompensationCurrent	11110000	usd
CY2023Q4	cort	Accrued Compensation Current AccruedCompensationCurrent	25457000	usd
CY2024Q1	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	3342000	usd
CY2023Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	1771000	usd
CY2024Q1	cort	Accrued Legal Fees Current AccruedLegalFeesCurrent	1362000	usd
CY2023Q4	cort	Accrued Legal Fees Current AccruedLegalFeesCurrent	542000	usd
CY2024Q1	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	997000	usd
CY2023Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	1078000	usd
CY2024Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	716000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	389000	usd
CY2024Q1	cort	Accrued Manufacturing Costs Current AccruedManufacturingCostsCurrent	157000	usd
CY2023Q4	cort	Accrued Manufacturing Costs Current AccruedManufacturingCostsCurrent	1455000	usd
CY2024Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1063000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	654000	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	59744000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	51628000	usd
CY2024Q1	cort	Deposits For Clinical Trials DepositsForClinicalTrials	6300000	usd
CY2023Q4	cort	Deposits For Clinical Trials DepositsForClinicalTrials	6400000	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	414182000	usd
CY2024Q1	us-gaap	Interest Receivable Current InterestReceivableCurrent	2000000	usd
CY2023Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	1700000	usd
CY2024Q1	cort	Marketable Securities Maximum Maturity Period MarketableSecuritiesMaximumMaturityPeriod	P27M
CY2024Q1	cort	Short Term Marketable Securities Maximum Maturity Period ShortTermMarketableSecuritiesMaximumMaturityPeriod	P1Y
CY2024Q1	cort	Marketable Securities Weighted Average Maturity Period MarketableSecuritiesWeightedAverageMaturityPeriod	P6M
CY2024Q1	cort	Loss Contingency Accrual Other LossContingencyAccrualOther	0	usd
CY2024Q1	cort	Loss Contingency Accrual Provision Other LossContingencyAccrualProvisionOther	0	usd
CY2024Q1	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P1M
CY2024Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	600000	usd
CY2023Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	600000	usd
CY2024Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	617000	usd
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	578000	usd
CY2024Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	297000	usd
CY2023Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2024Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4M
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3M
CY2024Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.080
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.040
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	77000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	77000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1000	usd
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	76000	usd
CY2024Q1	cort	Lessee Short Term Lease Liability To Be Paid Remainder Of Fiscal Year LesseeShortTermLeaseLiabilityToBePaidRemainderOfFiscalYear	700000	usd
CY2024Q1	cort	Number Of Stock Option Plans NumberOfStockOptionPlans	1	plan
CY2024Q1	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	45000	usd
CY2023Q1	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	92000	usd
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	13294000	usd
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	11233000	usd
CY2024Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	27514000	usd
CY2024Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	27514000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	15807000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	15807000	usd
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	102791000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	107885000	shares
CY2024Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	7124000	shares
CY2023Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	7540000	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	109915000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	115425000	shares
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.27
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.15
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.25
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.14
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	7200000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2600000	usd
CY2024Q1	us-gaap	Unrecognized Tax Benefits Period Increase Decrease UnrecognizedTaxBenefitsPeriodIncreaseDecrease	700000	usd

Files In Submission

Name	View Source	Status
0001628280-24-019610-index-headers.html	Edgar Link	pending
0001628280-24-019610-index.html	Edgar Link	pending
0001628280-24-019610.txt	Edgar Link	pending
0001628280-24-019610-xbrl.zip	Edgar Link	pending
cort-20240331.htm	Edgar Link	pending
cort-20240331.xsd	Edgar Link	pending
cort33124ex101ninthamendme.htm	Edgar Link	pending
cort33124ex102optime.htm	Edgar Link	pending
cort33124ex103zuorasublease.htm	Edgar Link	pending
cort33124ex311.htm	Edgar Link	pending
cort33124ex312.htm	Edgar Link	pending
cort33124ex321.htm	Edgar Link	pending
cort33124ex322.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_01.jpg	Edgar Link	pending
image_0a.jpg	Edgar Link	pending
image_1a.jpg	Edgar Link	pending
image_1b.jpg	Edgar Link	pending
image_2a.jpg	Edgar Link	pending
image_2b.jpg	Edgar Link	pending
image_3.jpg	Edgar Link	pending
image_4.jpg	Edgar Link	pending
image_5.jpg	Edgar Link	pending
image_6.jpg	Edgar Link	pending
image_7.jpg	Edgar Link	pending
image_8.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
cort-20240331_def.xml	Edgar Link	unprocessable
cort-20240331_htm.xml	Edgar Link	completed
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
cort-20240331_lab.xml	Edgar Link	unprocessable
cort-20240331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
cort-20240331_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CORT
Corcept Therapeutics Inc Stock $cort

2024 Q2 Form 10-Q Financial Statement

#000162828024019610 Filed on May 01, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CORT Corcept Therapeutics Inc Stock $cort

2024 Q2 Form 10-Q Financial Statement

#000162828024019610 Filed on May 01, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CORT
Corcept Therapeutics Inc Stock $cort